Physician profile

Michael L Gluck

Geriatric Medicine (Internal Medicine) · Lemoyne, PA

NPI 1437140837

$4,451.65

in general payments reported to CMS, 2019-2025

42 companies · $1,198 in 2025

The $1,198 reported for 2025 was more than what 91% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,296.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $968.81 2021-2025
Lilly USA, LLC $476.30 2019-2025 Zepbound, Mounjaro, Jardiance
Novo Nordisk INC $463.44 2019-2025 Rybelsus, Ozempic, Wegovy
Glaxosmithkline, LLC. $390.00 2019-2025 Shingrix, Arexvy, Trelegy Ellipta
E.R. Squibb & Sons, L.L.C. $239.79 2019-2025 Eliquis, Camzyos
Amgen INC. $189.82 2019-2025 Repatha, Otezla, Repatha
Phathom Pharmaceuticals, INC. $170.55 2024-2025 Voquezna
Exact Sciences Corporation $150.80 2023-2025 Cologuard Collection Kit
Comsort, INC $150.00 2019
Pfizer INC. $124.21 2019-2025
Novartis Pharmaceuticals Corporation $122.46 2019-2025
Merck Sharp & Dohme LLC $77.33 2019
Sumitomo Pharma America, INC. $61.54 2025 Gemtesa
Sunovion Pharmaceuticals INC. $57.52 2019
Astrazeneca Pharmaceuticals Lp $56.59 2019-2025 Airsupra, Breztri
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Amarin Pharma, INC. $53.44 2019
Paratek Pharmaceuticals, INC. $52.16 2024 Nuzyra
Janssen Pharmaceuticals, INC $48.54 2019-2020
Biofire Diagnostics, LLC $48.41 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $45.54 2025 Xifaxan
Astellas Pharma US INC $42.67 2020-2023 Myrbetriq
Ibsa Pharma INC. $40.86 2023-2025 Tirosint, Licart, Flector
Idorsia Pharmaceuticals US INC $38.66 2023 Quviviq
Sanofi Pasteur INC. $36.86 2019-2023
Teva Pharmaceuticals USA, INC. $33.73 2020-2024 Ajovy
Esperion Therapeutics, INC. $32.05 2025 Nexletol
Boehringer Ingelheim Pharmaceuticals, INC. $31.03 2023-2024 Jardiance, Synjardy, Tradjenta
Verona Pharma, INC. $26.95 2025 Ohtuvayre
Boston Scientific Corporation $23.14 2019
Strongbridge US INC. $19.50 2019
Nestle Healthcare Nutrition INC. $17.68 2023
Inspire Medical Systems, INC. $17.38 2023 Inspire
Daiichi Sankyo INC. $16.63 2019
Alexion Pharmaceuticals, INC. $16.42 2023 Ultomiris
Tactile Systems Technology INC $16.05 2023 Flexitouch Plus, Entre Plus
Vanda Pharmaceuticals INC. $14.58 2025 Fanapt
Cequr Corporation $14.40 2024 Cequr Simplicity
Acadia Pharmaceuticals INC $14.28 2023 Nuplazid
Alnylam Pharmaceuticals INC. $14.08 2023 Onpattro
Allergan, INC. $12.95 2019
Genentech USA, INC. $12.38 2019
Ironshore Pharmaceuticals INC. $12.12 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael L Gluck

$4,451.65

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $1,198 reported for 2025 was more than what 91% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).

https://glasscript.com/doctor/64410/michael-l-gluck

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.